Logo

    clopidogrel

    Explore " clopidogrel" with insightful episodes like "#20. Medicatie na een hartinfarct", "Episode 31- Antiplatelet agents in ACS: Who rules the roost?" and "CARDIOVASCULAR: TRITON-TIMI 38 Prasugrel Or Clopidogrel In Percutaneous Intevention?" from podcasts like ""Apothekers Podcast met Harm Geers", "ER-Rx: An ER + ICU Podcast" and "Audio Medica News - Medical News Interviews"" and more!

    Episodes (3)

    #20. Medicatie na een hartinfarct

    #20. Medicatie na een hartinfarct

    Na een hartinfarct wordt veel medicatie voorgeschreven, maar waarom wordt deze medicatie nu precies gebruikt? Eén van de veel gebruikt middelen na een hartinfarct is een bloedplaatjesremmer, of zelfs dubbele bloedplaatjesremming, waarom wordt dat toegepast en hoe lang moet dit gebruikt worden? Kunnen er ook drie verschillende antistollingsmiddelen gebruikt worden? U leert het allemaal in deze apothekerspodcast. 

    Episode 31- Antiplatelet agents in ACS: Who rules the roost?

    Episode 31- Antiplatelet agents in ACS: Who rules the roost?

    In this episode, we discuss the pros and cons of the main antiplatelet agents used in the setting of ACS. Who comes out on top?

    References:

    Norgard NB, DiNicolantonio JJ. Clopidogrel, prasugrel, or ticagrelor? A practical guide to use of antiplatelet agents in patients with acute coronary syndromes. Postgrad Med. 2013; 125(4): 91-102

    Thachil J. Antiplatelet therapy- a summary for the general physicians. Clin Med. 2016; 16(2): 152-160

    Disclaimer: 
    The information contained within the  ER-Rx podcast episodes, errxpodcast.com, and the @errxpodcast Instagram page is for informational/ educational purposes only, is not meant to replace professional medical judgement, and does not constitute a provider-patient relationship between you and the authors. Information contained herein may be accidentally inaccurate, incomplete, or outdated, and users are to use caution,  seek medical advice from a licensed physician,  and consult available resources prior to any medical decision making. The contributors of the ER-Rx podcast are not affiliated with, nor do they speak on behalf of,  any medical institutions, educational facilities, or other healthcare programs.

    Support the show

    Find ER-Rx:

    - On Instagram: @ERRxPodcast
    - On the website: errxpodcast.com
    - On YouTube

    Disclaimer:

    The information contained within the ER-Rx podcast episodes, errxpodcast.com, and the @errxpodcast Instagram page is for informational/ educational purposes only, is not meant to replace professional medical judgement, and does not constitute a provider-patient relationship between you and the authors. Information contained herein may be accidentally inaccurate, incomplete, or outdated, and users are to use caution, seek medical advice from a licensed physician, and consult available resources prior to any medical decision making. The contributors of the ER-Rx podcast are not affiliated with, nor do they speak on behalf of, any medical institutions, educational facilities, or other healthcare programs.

    CARDIOVASCULAR: TRITON-TIMI 38 Prasugrel Or Clopidogrel In Percutaneous Intevention?

    CARDIOVASCULAR: TRITON-TIMI 38 Prasugrel Or Clopidogrel In Percutaneous Intevention?
    Audio Journal of Cardiovascular Medicine, November 5th, 2007 Reporting from: American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida TRITON-TIMI 38 Prasugrel Or Clopidogrel In Percutaneous Intevention? GORDON TOMASELLI, Johns Hopkins University, Baltimore COMMENT: DANIEL JONES, President, American Heart Association, University of Mississippi, Jackson REFERENCE: Late Breaking Clinical Trials 1, AHA 2007 A potential new option for patients with acute coronary syndromes receiving coronary intervention has emerged following a report on the comparison of prasugrel, a new anti-platelet agent, with clopidogrel. Elliott Antman from Brigham and Women’s Hospital in Boston gave the American Heart Association his findings and recommendations about when and in which patients prasugrel might be favored. Gordon Tomaselli discussed the findings with Sarah Maxwell.
    Logo

    © 2024 Podcastworld. All rights reserved

    Stay up to date

    For any inquiries, please email us at hello@podcastworld.io